Streamline your pricing and reimbursement data management and analysis
Your Complete Market Access RepositoryAll the market access records you need are located in a single, interoperable repository. Effortlessly share information across your organization via a secure and consistent workflow using our integrated platform. Create different user profiles to tailor your Market Access Radar (MAR) repository. Receive further details with analysis from our local experts (personal assistance during service). Data is sourced and gathered from over 50 countries.
Spend your time on the pricing and reimbursement (P&R) strategy, not searching for relevant information
The intuitive interface guides users in visualizing data flow and analysis of P&R information. Deliver reproducible, quality results with automated workflows that can be saved, locked, customized, reused, and shared during your organization.
FREE TRIAL - 30 days of Market Access Radar
Market Access Radar (MAR), Professional – Free 30-day Trial!
For a limited time, gain free access to the industry’s deepest repository of market access-related decision-maker actions and published guidance for over 50 countries with more than 10 years of history:
- Save time. No need to conduct your own research, MAR’s one-stop shop brings data directly to you
- Increase productivity and focus on your P&R strategy rather than searching for relevant data
- Support from global market access specialists available as an add-on to provide expert interpretation or custom insight
- Stay informed of current & breaking news using our expert-curated repository of market access-related information
Supporting efficient P&R workflows
Market Access Radar (MAR) repository was created to provide you with quick and easy access to the most important market access related information. Insights presented in MAR follow an easy-to-follow layout to bring the most relevant data directly to you. We gather the latest reimbursement recommendations and information on financing from public funds announced by Ministries of Health (MOH) and Health Technology Assessment (HTA) agencies and changes in legal provisions regulating the financing of health technologies from public funds.
Compliant, integrated P&R records
News on drug safety, new marketing authorizations, variations in registered and reimbursed indications published by EMA, HMA, FDA, MHRA, Ministries of Health and other national institutions responsible for registration and safety of drugs and other valuable information which may impact reimbursement, published in mass media and relevant press.
役員紹介
Roman Casciano, MEng SVP Evidence & Access
Elvira Müller, PhD VP HTA and Evidence Development
Pascaline Faivre Senior Director Market Access
Jacek Walczak MD Vice President, EU Market Access
Roman Casciano, MEng SVP Evidence & Access
Elvira Müller, PhD VP HTA and Evidence Development
Pascaline Faivre Senior Director Market Access
Jacek Walczak MD Vice President, EU Market Access
Roman Casciano is Senior Vice President within Certara’s Evidence and Access Group. As an applied health economist and market access strategist, Roman has personally led hundreds of engagements in the international market access, HEOR and real world evidence context related to product value demonstration and has deep experience in both formal and informal exchanges with payers and HTA bodies.
Elvira is an expert in HTA engagements with substantial experience in health technology assessment, reimbursement strategy and early dialogues, both national and multi-HTA via the EUnetHTA collaboration.
Pascaline Faivre (PharmD, Msc) is a Senior Director Market Access at Certara and brings 13 years of experience in Market Access and Health economics at pharmaceutical industries and consultancy groups. Pascaline has successful track record of reimbursement submissions in EU countries, product launches, and extensive knowledge of EU market Access challenges and payers requirements for drugs, medical devices and vaccines.
Jacek Walczak co-founded Arcana Institute in Poland and holds the position of Vice President, EU Market Access at Certara in Poland. He has over 20 years of experience in systematic reviews, participating in over 200 HTA/market access projects and heading three international projects for the Leonardo Program. He has also served as an advisor for the Drug Policy Department at the Ministry of Health, co-authored Polish HTA guidelines and was an expert at the National Center for Quality Assessment. Jacek is a qualified orthopedic surgeon (Collegium Medicum of Jagiellonian University).
Roman Casciano is Senior Vice President within Certara’s Evidence and Access Group. As an applied health economist and market access strategist, Roman has personally led hundreds of engagements in the international market access, HEOR and real world evidence context related to product value demonstration and has deep experience in both formal and informal exchanges with payers and HTA bodies.
Elvira is an expert in HTA engagements with substantial experience in health technology assessment, reimbursement strategy and early dialogues, both national and multi-HTA via the EUnetHTA collaboration.
Pascaline Faivre (PharmD, Msc) is a Senior Director Market Access at Certara and brings 13 years of experience in Market Access and Health economics at pharmaceutical industries and consultancy groups. Pascaline has successful track record of reimbursement submissions in EU countries, product launches, and extensive knowledge of EU market Access challenges and payers requirements for drugs, medical devices and vaccines.
Jacek Walczak co-founded Arcana Institute in Poland and holds the position of Vice President, EU Market Access at Certara in Poland. He has over 20 years of experience in systematic reviews, participating in over 200 HTA/market access projects and heading three international projects for the Leonardo Program. He has also served as an advisor for the Drug Policy Department at the Ministry of Health, co-authored Polish HTA guidelines and was an expert at the National Center for Quality Assessment. Jacek is a qualified orthopedic surgeon (Collegium Medicum of Jagiellonian University).
